PatientsVille.com Logo


Eliquis Medical Research Studies

Up-to-date List of Eliquis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Eliquis Medical Research Studies

Rank Status Study
1 Recruiting Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
Condition: Non-valvular Atrial Fibrillation
Intervention: Drug: Apixaban
Outcome Measures: Percentage of days with a correct execution of the Apixaban dosing regimen during 24 weeks;   Within each study group, percentage of days with a correct execution of the Apixaban dosing regimen during the 12 to 24 weeks period compared with during the first 12 weeks;   Adherence to Apixaban dosing regimen during the 24 to 48 weeks in continued additional education group, secondary SOC group, and primary SOC group;   Risk factors indicative of non-adherence at 24 and 48 weeks;   Incidence of serious adverse events (AEs) and other AEs, including major bleeding (ISTH)
2 Not yet recruiting Early Post-marketing Study of Eliquis (Apixaban)
Condition: Non-valvular Atrial Fibrillation (NVAF)
Intervention: Drug: Apixaban
Outcome Measures: Determine the reporting rate of on-treatment adverse events (AEs) by the treating physicians;   Identify, describe, and report any suspected AEs that occur while on treatment with Apixaban or preventing stroke and systemic embolism in patients with NVAF
3 Not yet recruiting Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Conditions: Ischemic Stroke;   TIA
Interventions: Drug: Apixaban;   Drug: Clopidogrel;   Drug: Aspirin;   Drug: placebo
Outcome Measures: percentage of patients with new stroke (ischemic or hemorrhage);   Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death);   Changes in NIHSS scores;   moderate to severe bleeding events;   Total mortality;   Adverse events/severe adverse events reported by the investigators
4 Recruiting Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder
Condition: Thromboembolism
Intervention: Drug: Apixaban
Outcome Measures: Estimated area under the plasma concentration-time curve [AUC(INF)] of Apixaban;   Maximum estimated plasma concentration (Cmax) of Apixaban;   Estimated time at which maximum plasma concentration occurs (Tmax) of Apixaban;   Safety is measured by adverse event reports and the results of vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests;   Pharmacodynamics will be measured by anti-Factor Xa confirmed by analysis of anti-Factor Xa
5 Not yet recruiting A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
Condition: Anticoagulation
Interventions: Drug: Apixaban;   Drug: Cofact (4-Factor PCC);   Drug: Beriplex P/N (4-Factor PCC);   Drug: Placebo (Saline solution)
Outcome Measures: Pharmacodynamic Measure: Endogenous thrombin potential (ETP) change from pre-prothrombin complex concentrate (PCC) baseline and Day 1 pre-Apixaban baseline;   Pharmacodynamic Measures:Change from pre-PCC baseline and Day 1 pre-Apixaban baseline for other TGA parameters (Lag Time, Peak, Time to Peak and Velocity Index), PT, INR, aPTT and AXA;   Safety assessments based on medical review of adverse event reports and the results of vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests;   Multiple-dose pharmacokinetic parameter: Maximum observed plasma concentration (Cmax) of Apixaban;   Multiple-dose pharmacokinetic parameter: Time of maximum observed plasma concentration (Tmax) of Apixaban;   Multiple-dose pharmacokinetic parameter: Area under the concentration-time curve in one dosing interval [AUC(0-12)] of Apixaban;   Multiple-dose pharmacokinetic parameter: Area under the plasma concentration-time curve from time zero to 24 hours after dose administration [AUC(0-24)] of Apixaban;   Multiple-dose pharmacokinetic parameter: Trough observed plasma concentration at the end of one dosing interval (12h) [Cmin] of Apixaban;   Multiple-dose pharmacokinetic parameter: Terminal elimination half-life (T-HALF) of Apixaban
6 Not yet recruiting Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Condition: Atrial Fibrillation
Interventions: Drug: apixaban;   Drug: warfarin
Outcome Measures: Coronary Artery Calcium (CAC) score;   coronary plaque on CT angiography
7 Recruiting Eliquis Regulatory Post Marketing Surveillance
Intervention: Drug: Apixaban
Outcome Measure: Occurrence of stroke, systemic embolism and death
8 Recruiting Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
Condition: NonValvular Atrial Fibrillation
Intervention: Drug: Eliquis
Outcome Measures: Incidence rate of unexpected adverse events;   Bleeding events and risk factors of bleeding;   Ancillary baseline variables that may also be associated with adverse outcomes
9 Not yet recruiting Eliquis Regulatory Post Marketing Surveillance (rPMS)
Condition: Venous Thromboembolism
Intervention: Drug: Apixaban
Outcome Measure: Number of Adverse Events (AEs) and serious AEs
10 Recruiting Triple vs. Dual Therapy
Conditions: Atrial Fibrillation;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor + Apixaban + ASA;   Drug: Ticagrelor + Apixaban
Outcome Measures: β-thromboglobulin (β-TG);   Prothrombin fragment F1+2 (F1+2);   Thrombin-Anti-Thrombin (TAT);   D-dimer;   P-selectin
11 Not yet recruiting A Comparison of Apixaban Versus Aspirin for Preventing Stroke in Patients With Pacemakers
Conditions: Pacemaker, Artificial;   Defibrillators, Implantable;   Atrial Fibrillation;   Stroke
Interventions: Drug: Apixaban;   Drug: aspirin
Outcome Measures: Composite of ischemic stroke and systemic embolism;   Major bleeding
12 Recruiting Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
Conditions: Venous Thromboembolism;   Cancer
Interventions: Drug: Apixaban;   Drug: Placebo drug
Outcome Measures: first episode of objectively documented, symptomatic or asymptomatic VTE (DVT and/or PE);   Rate of adverse events
13 Recruiting A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
Condition: Bleeding
Interventions: Biological: Andexanet;   Other: Placebo
Outcome Measures: Reversal of Apixaban anticoagulation effect as measured by anti-factor Xa activity;   Unbound apixaban plasma levels;   Thrombin Generation
14 Recruiting Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Condition: Atrial Fibrillation
Interventions: Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Outcome Measures: Acute stroke;   Systemic embolism;   Major Bleeding;   Clinically Relevant Non-Major Bleeding;   All cause death;   Cardioversion Details;   Length of in-hospital stay;   Rhythm status
15 Not yet recruiting Apixaban in Patients With Sickle Cell Disease
Conditions: Vaso-occlusive Crisis;   Reduction in Hospitalizations;   Sickle Cell Disease
Interventions: Drug: Apixaban;   Drug: Placebo
Outcome Measures: Mean daily pain score in outpatients with SCD;   Change in thrombin generation from enrollment to 2 months following initiation of study drug.;   Comparison of daily pain scores while hospitalized between treatment arms;   Number of hospitalizations during each treatment period.
16 Not yet recruiting Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
Conditions: Myeloma;   Venous Thromboembolism
Intervention: Drug: Apixaban
Outcome Measures: Total VTE and VTE-related death. Major and clinically relevant non major bleeding - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis;   incidence of venous thromboembolic complications;   incidence of major and clinically relevant non major bleeding;   incidence of arterial cardiovascular events
17 Not yet recruiting Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Conditions: Anticoagulants;   Thromboembolism;   Hemorrhage
Interventions: Other: Measurement of Plasma Concentrations of NOACs;   Genetic: Identification of ABCB1 polymorphisms coding for P-gp
Outcome Measures: Measurement of plasma concentrations of new oral anticoagulant agents;   Identification of polymorphisms of the gene ABCB1 coding for P-gp
18 Recruiting Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Condition: Atrial Fibrillation
Intervention: Drug: Non-coumadin Oral Anticoagulant
Outcome Measures: Anticoagulant Utilization;   Bleeding rate
19 Recruiting Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Conditions: Severe Bleeding;   Urgent Surgery
Outcome Measures: Primary Outcome;   Secondary Outcome
20 Recruiting Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
Conditions: Venous Thromboembolism;   Atrial Fibrillation
Intervention: Other: complications and compliance with GIHP recommendations
Outcome Measures: complications and compliance with GIHP recommendations;   NOAC management;   reversal strategies description;   Coagulation test results

These studies may lead to new treatments and are adding insight into Eliquis etiology and treatment.

A major focus of Eliquis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Eliquis